ch.oddb.org
 
Apotheken | Doctor | Drugs | Hospital | Interactions | MiGeL | Registration owner | Services
Mezavant, 1,2 g magensaftresistente Retardtabletten - 60
65811001 Takeda Pharma AG
Mezavant, 1,2 g magensaftresistente Retardtabletten30.08.2016
  30.08.2016
Mesalazine (A07EC02) 
WHO-DDD 
04.09.60
04.09. 
B  
Yes 
IPCI
47.32No
    
10 %70.80
7680658110011Synthetika
6812383 
Composition
mesalazinum 1.2 g, carmellosum natricum, cera carnauba, acidum stearicum, silica colloidalis hydrica, carboxymethylamylum natricum A, talcum, magnesii stearas, Überzug: talcum, acidi methacrylici copolymerum A, acidi methacrylici copolymerum B, triethylis citras, macrogolum 6000, E 171, E 172 (rubrum) pro compresso obducto corresp. natrium 5.66 mg.
Packungsbestandteile
Active AgentDose
Mesalazine1.2 g
BAG: Active AgentDose
Mesalazine1.2 g
Inactive agentsDoseadditional_information
(Rubrum) pro Compresso Obducto  
Acidi Methacrylici Copolymerum A  
Acidi Methacrylici Copolymerum B  
Acidum Stearicum  
Carboxymethylamylum Natricum A  
Carmellose Sodium  
Cera Carnauba  
E 171 color.
E 172 color.
Macrogol6000  
Magnesii Stearas  
Silica Colloidalis Hydrica  
Talcum Überzug
Triethylis Citras  
 
Source
Data was imported : 06.09.2021 Swissmedic Registration : Sequence : Product name : Registration owner: : Product group : Index Therapeuticus (BSV) : Medication Code : Date of registration : Valid until : Package number : Show package size : Commercial Form/Unit : Swissmedic categorie. : Active Agents : Composition :
 
2024 ©ywesee GmbH
Settings | Help | FAQ | Login | Contact | Home